FDA Approves MEROPENEM — Fresenius Kabi USA, LLC

# FDA Approves Fresenius Kabi's Generic Meropenem Injectable Fresenius Kabi USA, LLC received FDA approval for its generic meropenem intravenous formulation, expanding the competitive landscape in the broad-spectrum carbapenem antibiotic market and potentially reducing treatment costs for hospitals and healthcare systems. The approval of the generic version is expected to increase price competition and improve patient access to this critical infection-fighting medication.